Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
- 1 April 2008
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 111 (7), 3531-3539
- https://doi.org/10.1182/blood-2007-08-109231
Abstract
We have prospectively evaluated the biologic response to desmopressin in 77 patients with type 1 von Willebrand disease (VWD) enrolled within the Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD project. Complete response to desmopressin was defined as an increase of both ristocetin cofactor activity (VWF:RCo) and factor VIII coagulant activity (FVIII:C) to 50 IU/dL or higher and partial response as VWF:RCo or FVIII:C lower than 50 IU/dL after infusion, but at least 3-fold the basal level. Complete response was observed in 83% of patients; partial in 13%; and no response in 4%. Patients with some abnormality of VWF multimeric pattern had significantly lower basal FVIII:C and VWF, lower VWF:RCo/Ag ratio, and less complete responses to desmopressin than patients with a normal multimeric pattern (P = .002). Patients with mutations at codons 1130 and 1205 in the D′-D3 domain had the greatest relative increase, but shortest FVIII and VWF half-lives after infusion. Most partial and nonresponsive patients had mutations in the A1-A3 domains. Response to desmopressin in these VWD patients seemed to be associated with the location of the causative mutation. The presence of subtle multimeric abnormalities did not hamper potential clinically useful responses, as in typical type 1 VWD.Keywords
This publication has 22 references indexed in Scilit:
- Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H‐M740I) defectJournal of Thrombosis and Haemostasis, 2006
- Cysteine-mutations in von Willebrand factor associated with increased clearanceJournal of Thrombosis and Haemostasis, 2005
- Treatment of von Willebrand diseaseSeminars in Hematology, 2005
- Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European studyBlood, 2004
- Reduced von Willebrand factor survival in type Vicenza von Willebrand diseaseBlood, 2002
- Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMPJCI Insight, 2000
- Prevalence of von Willebrand disease in children: A multiethnic studyThe Journal of Pediatrics, 1993
- Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia ABlood, 1989
- Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra-platelet von Willebrand factorEuropean Journal of Haematology, 1988
- Epidemiological investigation of the prevalence of von Willebrand's diseaseBlood, 1987